Display options
Cite
Rios J, Gosain R, Goulart BH, et al. Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. Cancer Manag Res. 2018;10:167-175doi: 10.2147/CMAR.S151935.
Rios, J., Gosain, R., Goulart, B. H., Huang, B., Oechsli, M. N., McDowell, J. K., Chen, Q., Tucker, T., & Kloecker, G. H. (2018). Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. Cancer management and research, 10167-175. https://doi.org/10.2147/CMAR.S151935
Rios, Jorge, et al. "Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity." Cancer management and research vol. 10 (2018): 167-175. doi: https://doi.org/10.2147/CMAR.S151935
Rios J, Gosain R, Goulart BH, Huang B, Oechsli MN, McDowell JK, Chen Q, Tucker T, Kloecker GH. Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity. Cancer Manag Res. 2018 Jan 24;10:167-175. doi: 10.2147/CMAR.S151935. eCollection 2018. PMID: 29416376; PMCID: PMC5789001.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2018 Jan 24;10:167-175. doi: 10.2147/CMAR.S151935. eCollection 2018.

Treatment and outcomes of non-small-cell lung cancer patients with high comorbidity.

Cancer management and research

Jorge Rios, Rahul Gosain, Bernardo Hl Goulart, Bin Huang, Margaret N Oechsli, Jaclyn K McDowell, Quan Chen, Thomas Tucker, Goetz H Kloecker

Affiliations

  1. James Graham Brown Cancer Center, University of Louisville, Louisville, KY.
  2. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
  3. Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY.
  4. Markey Cancer Center, University of Kentucky, Lexington, KY, USA.

PMID: 29416376 PMCID: PMC5789001 DOI: 10.2147/CMAR.S151935

Abstract

BACKGROUND: The life expectancy of untreated non-small-cell lung cancer (NSCLC) is dismal, while treatment for NSCLC improves survival. The presence of comorbidities is thought to play a significant role in the decision to treat or not treat a given patient. We aim to evaluate the association of comorbidities with the survival of patients treated for NSCLC.

METHODS: We performed a retrospective study of patients aged ≥66 years with invasive NSCLC between the years 2007 and 2011 in the Surveillance, Epidemiology, and End Results Kentucky Cancer Registry. Comorbidity was measured using the Klabunde Comorbidity Index (KCI), and univariate and multivariate logistic regression models were used to measure association between receiving treatment and comorbidity. Kaplan-Meier plots were constructed to estimate time-to-event outcomes.

RESULTS: A total of 4014 patients were identified; of this, 94.9% were white and 55.7% were male. The proportion of patients who did not receive any treatment was 8.7%, 3.9%, 19.1%, and 23.5% for stages I, II, III, and IV, respectively (

CONCLUSION: Our data suggest that lung cancer patients may derive a survival benefit from therapies, regardless of the presence of comorbidities, although the degree of benefit seems to decrease with higher KCI scores.

Keywords: Klabunde; cancer; comorbidity index; lung cancer; non-small-cell lung cancer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Cancer. 2012 Dec 1;118(23):5947-54 - PubMed
  2. Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1079-85 - PubMed
  3. Cancer. 2014 May 1;120(9):1290-314 - PubMed
  4. J Clin Oncol. 2008 Jul 20;26(21):3543-51 - PubMed
  5. J Oncol Pract. 2013 Jan;9(1):42-50 - PubMed
  6. Clin Lung Cancer. 2011 Jul;12(4):207-11 - PubMed
  7. Chest. 2007 Jul;132(1):193-9 - PubMed
  8. Ann Oncol. 2014 May;25(5):1044-52 - PubMed
  9. Lancet Oncol. 2012 Mar;13(3):239-46 - PubMed
  10. Ann Oncol. 2015 Sep;26(9):1877-83 - PubMed
  11. Cancer Metastasis Rev. 2003 Mar;22(1):39-46 - PubMed
  12. J Clin Oncol. 2013 Dec 1;31(34):4349-57 - PubMed
  13. J Thorac Oncol. 2015 Feb;10(2):272-9 - PubMed
  14. Chest. 2014 Feb;145(2):346-353 - PubMed
  15. J Thorac Oncol. 2014 Jun;9(6):812-7 - PubMed
  16. Int J Cancer. 2003 Mar 1;103(6):792-802 - PubMed
  17. Eur J Cancer. 2012 Dec;48(18):3386-95 - PubMed
  18. Radiother Oncol. 2013 Oct;109(1):100-6 - PubMed
  19. J Clin Epidemiol. 2000 Dec;53(12):1258-67 - PubMed

Publication Types